ReviewJournal of thoracic disease2020
Paraneoplastic syndromes in small cell lung cancer.
Review in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Endocrine and paracrine characteristics of neuroendocrine prostate cancer.Frontiers in endocrinology · 2022Pooled it
- Article
- Paraneoplastic neurologic syndrome in a 65-year-old woman with small cell lung cancer.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Paraneoplastic neurologic syndrome in advanced lung cancer with mixed adenocarcinoma and squamous features: a diagnostic challenge-a case report.Journal of medical case reports · 2026Article
- A Rare Oral Metastatic Lesion as the Initial Diagnosis of Small Cell Lung Cancer: Case Report and Systematic Review.Journal of clinical medicine · 2026Review
- Unexpected Link Between Myasthenia Gravis and Lung Adenocarcinoma: A Case Report.Case reports in surgery · 2026Article
- Article
- Article
- Clinical characteristics and survival of patients with calcitonin-secreting neuroendocrine neoplasms: experience from a series of 71 patients.Endocrine · 2025Article
- Endocrinology and the Lung: Exploring the Bidirectional Axis and Future Directions.Journal of clinical medicine · 2025Article
- Article
- Recent research advances in interleukin, microRNA and neuroendocrine tumor biomarkers (Review).Molecular and clinical oncology · 2025Review
- Review
- Translocation of gut bacteria promotes tumor-associated mortality by inducing immune-activated renal damage.The EMBO journal · 2025Article
- A Neuropsychiatric Prelude to Unveiling Small Cell Lung Cancer with Suspected Paraneoplastic Limbic Encephalitis: A Case Report.Current oncology (Toronto, Ont.) · 2025Article
- Catecholamine-Secreting Non-small Cell Lung Cancer Presenting With Hypertensive Crisis: A Report of a Rare Case.Cureus · 2025Article
- A SEER prognostic nomogram analysis for extensive-stage small cell lung cancer: comparing the immune checkpoint inhibitors (ICIs) and non-ICIs eras.Journal of thoracic disease · 2025Article
- Accelerating and protective effects toward cancer growth in cGAS and FcgRIIb deficient mice, respectively, an impact of macrophage polarization.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Endocrine paraneoplastic syndromes in lung cancer: A call for clinical vigilance (Review).Molecular and clinical oncology · 2025Review
- Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors.Immunotherapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic syndromes can commonly occur due to lung cancer, especially small cell lung cancer. Frequently paraneoplastic syndromes can precede the diagnosis of the neoplasm or present with limited stage disease. However, these syndromes can also occur at the time of recurrence or metastasis of disease. This review focuses on the epidemiology, pathogenesis, clinical features, and current management of the most common paraneoplastic syndromes encountered in patients with small cell lung cancer. Manifestations of paraneoplastic syndromes in small cell lung cancer include endocrine syndromes with secretion of excess hormones, and neurologic syndromes due to the production of antibodies causing an autoimmune condition. Recent advances have allowed for greater understanding of these syndromes and for the development of improved diagnostic as well as therapeutic tools. Awareness of paraneoplastic syndromes in small cell lung cancer can lead to an earlier diagnosis and recognition of both the condition and in some cases the disease potentially improving the overall survival and prognosis for patients. Further research examining effective methods to improve recovery from neurologic deficits in patients with a paraneoplastic neurologic illness is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.